Intranasal formulations for treating obstructive sleep apnea
Intranasal administration of AVE-118 combined with mucoadhesive polymers addresses the limitations of current OSA treatments by providing effective reduction in upper airway collapsibility, offering a promising new therapy for obstructive sleep apnea.
WO2025068591A1 Publication Date: 2025-04-03MOSANNA THERAPEUTICS AG
6 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2024/077436
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-16
- Filing Date
- 2024-09-30
- Publication Date
- 2025-04-03
AI Technical Summary
Technical Problem
Current treatments for obstructive sleep apnea (OSA) have limited efficacy and poor patient compliance, and existing pharmacologic approaches using intranasal potassium channel blockers have shown mixed results.
Method used
Development of pharmaceutical compositions comprising the potassium channel blocker AVE-118, or a pharmaceutically acceptable salt thereof, combined with a mucoadhesive polymer for intranasal administration, which allows effective treatment of OSA by reducing upper airway collapsibility.
Benefits of technology
The use of microparticulate suspensions of AVE-118 with mucoadhesive polymers provides sustained efficacy in reducing upper airway collapsibility, even after nasal lavage, offering a potential new therapy for OSA.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to nasal pharmaceutical compositions for the treatment of obstructive sleep apnea, drug-device combinations for intranasal delivery of the pharmaceutical compositions, and methods of treatment.
Need to check novelty before this filing date? Find Prior Art